This title appears in the Scientific Report :
2014
Please use the identifier:
http://hdl.handle.net/2128/9167 in citations.
Characterization of D-enatiomeric peptides derived from D3 for treatment of Alzheimer`s disease
Characterization of D-enatiomeric peptides derived from D3 for treatment of Alzheimer`s disease
Alzheimer's disease (AD) is the most prominent neurodegenerative disease affecting more than 24 million people worldwide. Currently, it is the sixth-leading cause of death, but until now there is no causal therapy available. The amyloid-beta (Aβ) peptide plays an important role in the pathology...
Saved in:
Personal Name(s): | Klein, Antonia Nicole |
---|---|
Tusche, Markus / Schlosser, Christine / Bartnik, Dirk / Kutzsche, Janine / Willbold, Dieter (Corresponding Author) | |
Contributing Institute: |
Strukturbiochemie; ICS-6 |
Published in: | 2014 |
Imprint: |
2014
|
Conference: | Alzheimer`s Association International Conference 2014, Copenhagen (Denmark), 2014-07-13 - 2014-07-13 |
Document Type: |
Poster |
Research Program: |
Structural Biology |
Link: |
Get full text OpenAccess |
Publikationsportal JuSER |
Alzheimer's disease (AD) is the most prominent neurodegenerative disease affecting more than 24 million people worldwide. Currently, it is the sixth-leading cause of death, but until now there is no causal therapy available. The amyloid-beta (Aβ) peptide plays an important role in the pathology of the disease. Especially the soluble, most harmful neurotoxic oligomers of Aβ are discussed to be responsible for the development and progression of the disease. In our group we identified the D-enantiomeric peptide D3 via mirror image phage display, which reduces the formation of Aβ oligomers in vitro [1-3]. |